retatrutide patent 🎥 Eli Lilly’s next generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the How to Survive the GLP-1

doi: 10.3390/antiox14010074 271 RasmannS.AliJ

Youre going to be a parent!

To conclude, MEDI4166 has been engineered to be a novel long acting GLP-1R agonist peptide with a reduced potency in fusion with an optimized neutralising anti-PCSK9 antibody to deliver glycaemic and weight control in combination with LDL-C lowering

doi: 10.1161/CIRCULATIONAHA.111.019927 Summary Keywords eryptosis, Plasmodium , malaria, cell death, eryptosis inducers, phosphatidylserine exposure, erythrocyte (human) Citation Boulet C, Gaynor TL and Carvalho TG (2021) Eryptosis and Malaria: New Experimental Guidelines and Re-Evaluation of the Antimalarial Potential of Eryptosis Inducers

Bottom line GLP-1 medications, or glucagon-like peptide-1 receptor agonists, treat type 2 diabetes and, in some cases, obesity